| A novel cell therapy for stress urinary incontinence, short-term outcome. | |
| | |
MedLine Citation:
|
PMID: 22972395 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
AIMS: The aim of this study was the safety assessment of urethra injections of autologous total nucleated cells (TNCs) along with platelets, which focused on the outcome over a 6 month period. METHODS: An open, prospective study was conducted on 9 patients with severe stress urinary incontinence (SUI). At the baseline, 1, 3, and 6 months after external urethral sphincteric and submucosal injections of autologous TNCs along with platelets, the patients were assessed according to cough tests, Q-Tip tests, urodynamics, 1 hr pad tests, upper tract ultrasonography (UTU), post voiding residue (PVR), International Consultation on Incontinence Questionnaire-Urinary incontinence (ICIQ-UI), and International Consultation on Incontinence Modular Questionnaire-Quality of Life (ICIQ-QOL). On the 3rd month post-injection, the maximum urethral closure pressure (MUCP) and abdominal leak point pressure (ALPP) were measured in one patient with intrinsic sphincteric deficiency (ISD; the baseline: ALPP < 60 and MUCP < 30 cmH(2) O). RESULTS: No complications were observed after injection. At 6-months' follow up (F/U), all the patients considered themselves clinically cured with eight women completely continent and one marked improvement. Mean age was 48.9 ± 13.8 years. Before the injection, urodynamics, UTU, and PVR were normal and cough tests, 1 hr pad tests were positive in patients. At 1, 3, and 6 months post-injection, there was a significant improvement in ICIQ-UI, ICIQ-QOL (P < 0.05). UTU and PVR were normal, cough tests, and 1 hr pad tests were negative, except for ISD patient with severe coughs (at month 3: ALPP = 92 and MUCP > 30 cmH(2) O). CONCLUSION: Cell therapy consisting of intrasphincteric and submucosal injections of autologous TNCs along with platelets in SUI patients is a feasible and safe procedure. The results point out those subjects cured or with marked improvement after 6 months F/U. Neurourol. Urodynam. © 2012 Wiley Periodicals, Inc. |
| | |
Authors:
|
Maliheh Keshvari Shirvan; Daryoush Hamidi Alamdari; Mohammadreza Darabi Mahboub; Alireza Ghanadi; Hamid Reza Rahimi; Alexander M Seifalian |
Related Documents
:
|
23403545 - Comparison of quality of life in head and neck stage iv squamous cell cancer patients t... 2877505 - Conservative treatment of external pancreatic fistulas with parenteral nutrition alone ... 17897575 - Benign biliary strictures related to chronic pancreatitis: balloons, stents, or surgery. 8422855 - Valproate-associated pancreatitis. 7518975 - Nephrotoxicity following orthotopic liver transplantation. a comparison between cyclosp... 11056425 - Lichen striatus: clinical features and follow-up in 12 patients. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-9-12 |
Journal Detail:
|
Title: Neurourology and urodynamics Volume: - ISSN: 1520-6777 ISO Abbreviation: Neurourol. Urodyn. Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-9-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8303326 Medline TA: Neurourol Urodyn Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Wiley Periodicals, Inc. |
Affiliation:
|
Department of Urology, Imam Reza Academic Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hong's grading for evaluating anterior chamber angle width.
Next Document: Luminescent Neutral Platinum Complexes Bearing an Asymmetric N(^) N(^) N Ligand for High-Performance...